The economic cost of care in poor graft function following allogeneic stem cell transplantation

Manu Juneja,Ashvind Prabahran,Mayani Rawicki,Lynette C. Y. Chee,Rachel M. Koldej,David S. Ritchie
DOI: https://doi.org/10.1038/s41409-024-02452-7
2024-10-25
Bone Marrow Transplantation
Abstract:Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for diseases including myelodysplastic syndrome, leukaemia and lymphoma. However, the cost and resource requirements of alloSCT is significant, totalling to in excess of $250,000USD in the United States [1, 2]. Poor graft function (PGF), defined as multilineage cytopenias in the presence of complete donor chimerism, is a significant complication of alloSCT [3]. The incidence of PGF is estimated to vary between 5–11% of patients receiving alloSCT, depending on factors including donor type, conditioning regimen and underlying disease [4, 5]. Those afflicted by PGF are reliant on extended supportive care until marrow recovery and have significantly lower overall survival [5]. We have previously explored the bone marrow pathologies that potentiate PGF namely: (1) the quality and quantity of donor haematopoietic stem cells; (2) the residual bone marrow microenvironment following conditioning and; (3) immune dysfunction persisting following transplant [6]. However, the impact of PGF on cumulative healthcare costs has not previously been examined.
oncology,immunology,hematology,transplantation
What problem does this paper attempt to address?